Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).

Martin SoubrierBruno PereiraAngelique FanThomas FrayssacMarion CoudercSandrine Malochet-GuinamandSylvain MathieuZuzana TatarAnne TournadreJean-Jacques Dubost

Published in: International journal of rheumatic diseases (2018)

The retention rate in SpA patients proved high, with retention for IFX superior to that of ETN.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
rheumatoid arthritis
healthcare
prognostic factors
peritoneal dialysis
primary care
physical activity
systemic lupus erythematosus
patient reported outcomes
ulcerative colitis